HR Execs on the Move

MediSystem Technologies

www.imedisystem.com

 
MediSystem Technologies Inc. is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Sinai Residences

Sinai Residences is a retirement community in Boca Raton that offers luxurious surroundings and a culture of sophistication. They provide top-notch independent and assisted living, memory care, rehab, and skilled nursing services on site.

Medcorp Innovations

Medcorp Innovations is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HumanTouch

Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive training, thousands of chiropractors who integrate a therapeutic massage on a Human Touch massage chair into their professional services, back pain sufferers looking to reduce their aches and pains, and everyday people looking for a respite from the stress of today`s lifestyle.

Ascend Healthcare

Ascend Healthcare is a residential treatment facility for teens struggling with mental health and addiction issues. They provide evidence-based therapies, experiential therapies, and a unique clinical approach to help their clients. Their focus on fami...

Afferent Pharmaceuticals

Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.